The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 ...

1. Tanaka, M., Yokoyama, T., Saito, H., Nishimoto, M., Tsuda, K., Sotta, N., Shigematsu, H., Shirouzu, M., Iwasaki, S., Ito, T. and Fujiwara, T.: “Boric acid ...

2012;7(1):81-92. These recent findings have two important implications. First, simple measurements of eIF2B GEF activity in samples from patient-derived cells do not appear to be a suitable ...

Could this be the key to new therapies? In response to impaired eIF2B function, cells reduce phosphorylation of eIF2£\ (eIF2£\-p), a crucial regulator of the integrated stress response (ISR).

The therapy, dubbed DNL343, is designed to activate the protein complex eIF2B, protecting neurons by preventing further aggregation of the TDP-43 protein. A phase 2/3 readout from a Massachusetts ...

Elevated p-eIF2α, and its proper sensing by the decameric eIF2B complex, are essential to balance translation. Knockdown or mutation of eIF2Bα and eIF2Bδ, two eIF2B subunits responsible for sensing ...

Vanishing white matter (VWM) is caused by mutations in the genes for eIF2B, an important regulator of protein synthesis. VWM mutations affect the function of eIF2B in diverse ways; recent data ...

Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit. Massachusetts General Hospital found neither AbbVie and ...